Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 07 2023
Historique:
pmc-release: 27 12 2023
medline: 17 7 2023
pubmed: 27 6 2023
entrez: 27 6 2023
Statut: ppublish

Résumé

The concept of a mild mutagen was coined to describe a minor mutagenic activity exhibited by some nucleoside analogues that potentiated their efficacy as antiretroviral agents. In the present study, we report the mild mutagen activity of sofosbuvir (SOF) for hepatitis C virus (HCV). Serial passages of HCV in human hepatoma cells, in the presence of SOF at a concentration well below its cytotoxic concentration 50 (CC

Identifiants

pubmed: 37367486
doi: 10.1128/aac.00394-23
pmc: PMC10353389
doi:

Substances chimiques

Sofosbuvir WJ6CA3ZU8B
Mutagens 0
Antiviral Agents 0
Ribavirin 49717AWG6K

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0039423

Références

PLoS One. 2018 Oct 3;13(10):e0204877
pubmed: 30281674
Genome Biol Evol. 2017 May 1;9(5):1212-1228
pubmed: 28460010
Future Med Chem. 2019 Jul;11(13):1645-1657
pubmed: 31469331
Virology. 2016 Jun;493:227-37
pubmed: 27060566
Science. 2005 Jul 22;309(5734):623-6
pubmed: 15947137
J Mol Med (Berl). 2002 Feb;80(2):86-95
pubmed: 11907645
PLoS Med. 2018 Mar 27;15(3):e1002535
pubmed: 29584730
J Virol. 2017 Apr 28;91(10):
pubmed: 28275194
Antivir Ther. 2017;22(7):587-597
pubmed: 28248189
Nat Biotechnol. 2010 Feb;28(2):167-71
pubmed: 20118917
J Virol. 2014 Oct;88(20):12098-111
pubmed: 25122776
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4448-52
pubmed: 15767582
J Virol. 2000 Sep;74(18):8316-23
pubmed: 10954530
Virology. 2018 Oct;523:100-109
pubmed: 30107298
Viruses. 2022 Apr 18;14(4):
pubmed: 35458571
Annu Rev Microbiol. 2004;58:183-205
pubmed: 15487935
BMC Infect Dis. 2018 Sep 3;18(1):446
pubmed: 30176817
J Virol. 2013 Jul;87(13):7593-607
pubmed: 23637397
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68
pubmed: 22430955
Bioorg Med Chem. 2013 Nov 15;21(22):7222-8
pubmed: 24120088
Curr Top Microbiol Immunol. 2023;439:1-94
pubmed: 36592242
Sci Rep. 2017 Jan 18;7:40920
pubmed: 28098253
J Biol Chem. 2007 Oct 12;282(41):29812-20
pubmed: 17698842
Evolution. 1990 Nov;44(7):1725-1737
pubmed: 28567811
Trends Microbiol. 2013 Feb;21(2):56-62
pubmed: 23195922
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7
pubmed: 9990051
Virus Res. 2017 Jul 15;239:115-125
pubmed: 28040474
J Theor Biol. 1989 Apr 20;137(4):375-95
pubmed: 2626057
Front Mol Biosci. 2022 Jan 25;8:823253
pubmed: 35145998
Antiviral Res. 2020 Feb;174:104694
pubmed: 31857134
Biology (Basel). 2022 Apr 30;11(5):
pubmed: 35625421
Antimicrob Agents Chemother. 2016 May 23;60(6):3786-93
pubmed: 27067341
Bioinformatics. 2014 Apr 15;30(8):1104-1111
pubmed: 24389655
Hepatology. 2008 Dec;48(6):1843-50
pubmed: 19003912
J Med Chem. 2022 Nov 10;65(21):14261-14275
pubmed: 36282210
Evolution. 2020 Dec;74(12):2549-2559
pubmed: 33047822
J Virol. 2002 Dec;76(24):13001-14
pubmed: 12438626
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Clin Pharmacokinet. 2015 Jul;54(7):677-90
pubmed: 25822283
Virus Res. 2005 Feb;107(2):173-81
pubmed: 15649563
Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45
pubmed: 24733478
Br J Clin Pharmacol. 2017 Feb;83(2):269-293
pubmed: 27530469
Curr Opin Virol. 2014 Oct;8:10-5
pubmed: 24846716
Elife. 2014 Oct 21;3:e03679
pubmed: 25333492
J Virol. 2013 Apr;87(7):3741-51
pubmed: 23325689
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29439971
PLoS Pathog. 2010 Aug 26;6(8):e1001072
pubmed: 20865120
J Med Chem. 2010 Oct 14;53(19):7202-18
pubmed: 20845908
Nat Med. 2000 Dec;6(12):1375-9
pubmed: 11100123
J Chromatogr Sci. 2016 Oct 17;54(9):1631-1640
pubmed: 27436268
Viruses. 2021 Apr 03;13(4):
pubmed: 33916702
PLoS One. 2016 Oct 18;11(10):e0164691
pubmed: 27755573
Antimicrob Agents Chemother. 2002 Apr;46(4):977-81
pubmed: 11897578
J Mol Biol. 2008 Oct 10;382(3):652-66
pubmed: 18662697
Hepatology. 2015 Nov;62(5):1623-32
pubmed: 26095927
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900
pubmed: 11371613
Virology. 2016 Jul;494:257-66
pubmed: 27136067
J Virol. 2020 Feb 28;94(6):
pubmed: 31852791

Auteurs

Brenda Martínez-González (B)

Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain.

Isabel Gallego (I)

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Josep Gregori (J)

Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

María Eugenia Soria (ME)

Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain.

Pilar Somovilla (P)

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Departamento de Biología Molecular, Universidad Autónoma de Madrid, Madrid, Spain.

Ana Isabel de Ávila (AI)

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Carlos García-Crespo (C)

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Antoni Durán-Pastor (A)

Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Carlos Briones (C)

Centro de Astrobiología (CAB, CSIC-INTA), Madrid, Spain.

Jordi Gómez (J)

Instituto de Parasitología y Biomedicina 'López-Neyra' (CSIC), Parque Tecnológico Ciencias de la Salud, Granada, Spain.

Josep Quer (J)

Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain.
Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

Esteban Domingo (E)

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Celia Perales (C)

Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH